Apoptosis: mitochondria resurrected? by unknown
Commentary 
Apoptosis:  Mitochondria  Resurrected? 
By Pierre A. Henkart* and Sergio Grinstein* 
From the *Experimental Immunology Branch, National Cancer Institute, National Institutes of 
Health, Bethesda, Maryland, 20892; and *Division of Cell Biology, Hospital  for Sick Chlidren, 
Toronto, Ontario, Canada, M5G 1X8 
A 
lthough apoptosis research has become a very vigorous 
field over the last several years, fundamental questions 
about this type of cell death remain unanswered.  Principal 
among these is whether there is a central core of biochemi- 
cal steps that are shared by the apoptotic deaths elicited in 
diverse cell types by different stimuli.  For some time the 
protective actions of Bcl-2 in a variety of apoptotic death 
systems seemed to provide the most suggestive evidence in 
favor of this hypothesis (1),  particularly because this mole- 
cule seems to be related functionally and structurally to the 
product of the Caenorhabditus elegans death-protectant gene 
ced-9. The simplicity of this model can be questioned, since 
there are a significant number of cases where Bcl-2 expres- 
sion  fails  to  protect  against  apoptotic  death.  However,  it 
has been realized recently that Bcl-2 is only one member of 
a  family of dimerizing proteins  that  influence  cell  death. 
Some, like Bax, enhance death rather than block it (2), re- 
vealing  a  complex  balance  of  agonists  and  antagonists. 
Thus,  the  failure  of Bcl-2  to  protect  against  apoptosis  in 
some cases can be rationalized by postulating that there are 
additional  parallel  death  pathways  that  are  regulated  by 
other species that are related to yet distinct from Bcl-2. It is 
reasonable to suppose that the molecular targets of the Bcl-2 
family members are part of a pathway leading to apoptotic 
death, which is common from nematodes to man. Bax and 
its relatives could fill this role. 
One model proposed to explain the protective activity of 
Bcl-2 was that it acts as an antioxidant (3), neutralizing the 
effects of reactive oxygen species (P,  OS) 1, which are effec- 
tor  molecules  common  to  various  apoptotic  death  path- 
ways (4).  Immunolocalization studies showed that the pri- 
mary site of intracellular Bcl-2 was the mitochondrial outer 
membrane.  This  suggested  that  Bcl-2  might  function  to 
protect cells from P, OS generated as a normal by-product 
of mitochondrial oxidation reactions during the  course of 
ATP biosynthesis. It seemed plausible that the cytoplasmic- 
facing Bcl-2 could also protect against cytoplasmic oxidants 
involved in  mediating  apoptotic  death,  and  it  is  hard  to 
imagine a more effective way to kill a cell than to burn it! 
ROS generation associated with apoptotic death has indeed 
been reported in steroid-treated T  hybridoma cells  and in 
the  TNF-mediated death  of tumor cells  (3,  5).  Failure  to 
1Abbreviations used in this paper: ICE, IL-l[3-converting enzyme; PT, per- 
meability transition; ROS, reactive oxygen species. 
observe kOS generation in other forms of apoptosis can be 
rationalized if the event were highly localized.  Additional 
supporting evidence for R.OS as apoptotic effectors comes 
from demonstrations that endogenous and exogenous anti- 
oxidants can block various types of apoptotic death  (4,  6, 
7).  Nevertheless,  although  P,.OS  seem to  be  involved in 
some examples of apoptotic death, they are likely to be part 
of upstream signafing events in particular cases,  rather than 
essential elements of a common downstream death-effector 
pathway  blocked  by  Bcl-2.  Thus,  glutathione  depletion 
sensitizes HL-60 cells to apoptotic death induced by some 
agents but not others (8), and antioxidants protect T  hybri- 
doma cells  against TCP,-induced death (9),  but not at the 
terminal stage triggered by Fas-crosslinking (10). 
In view of these  shortcomings,  investigators have pur- 
sued  the  search  for apoptotic  effectors  other  than  ROS. 
During the last 2 yr, cysteine proteases with "asp-ase" ac- 
tivity emerged as candidates for common apoptotic effector 
molecules.  The  prototype  of this  family is  the  C.  elegans 
death  gene ced-3, the  mutation  of which  blocks develop- 
mental death in many different cells. Mammalian members 
of this family, which have homology to IL-l-[3-converting 
enzyme (ICE), are being rapidly described. These proteases 
are synthesized as precursors, which  need to be processed 
via cleavage at aspartic acid residues to acquire proteolytic 
activity.  One  can  therefore  envision  complex  parallel  or 
converging proteolytic  cascades involved in  apoptosis.  At 
this stage, however, it is not clear what controls their acti- 
vation,  nor  the  nature  of the  substrates  relevant  to  cell 
death.  Although  nuclear  substrates  such  as  poly  (ADP- 
ribose)  polymerase  and  DNA-dependent  protein  kinase 
may well contribute to the  classical  apoptotic DNA dam- 
age,  experiments with  enucleated  cells  indicate  that  such 
damage is  not  required  for some  forms  of apoptotic  cell 
death,  like  that  triggered by Fas  (11).  The  principal  evi- 
dence  that  the  ICE-like  protease  family  has  a  common 
apototic  effector  function  comes  from  experiments  in 
which protein inhibitors  of these proteases have been ex- 
pressed in a variety of cell types and found to block apop- 
totic death. The cowpox virus protein CrmA and the bac- 
ulovirus protein p35 both inhibit ICE and other ICE-like 
proteases  (12-14)  (but  not  necessarily all  [15])  and block 
developmental cell death, as well as that induced by growth 
factor withdrawal and other agents such as anti-Fas and ste- 
roids (16-21). In addition, peptide-based inhibitors of ICE- 
like  proteases  block  other  varied  examples  of apoptotic 
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not blocked by inhibitors of ICE-like proteases, namely, T 
cell  death  by  IL-2  withdrawal  (26)  and  steroid-induced 
death of a T  hybridoma (27).  The significance of these ob- 
servations is difficult to assess given our incomplete knowl- 
edge of the specificity of the  protease inhibitors.  Overall, 
ICE-like protease inhibitors seem more generally potent in 
their ability to block death than does Bcl-2, and one simple 
way to explain this is to postulate that these proteases act 
downstream of the site of Bcl-2 inhibition. 
The emergence of the ICE-like proteases detracted from 
the early interest in R.OS and mitochondria. The loss of in- 
terest was accentuated by several observations.  First,  some 
examples of apoptotic death persist when cells are depleted 
of oxygen to reduce generation of ROS  (28,  29).  Second, 
preservation  of "normal"  mitochondrial  morphology  has 
been considered a hallmark of apoptotic death.  The third 
and most important hne of evidence came from studies of 
cells  grown  under  conditions  in  which  mitochondrial 
DNA  replication  was  suppressed.  These  cells,  termed  p~ 
lack  important  components  of the  respiratory  chain,  the 
source of mitochondrial R.OS.  In such cells,  staurosporine 
triggered  apoptotic  death,  and  Bcl-2  expression  still  af- 
forded protection  (30).  Together,  these  hnes  of evidence 
argued that mitochondrial-generated I<OS are not part of a 
common downstream apoptotic effector pathway, and mi- 
tochondria were thus dismissed, with some rehef by many 
in the field. However, the article in this issue of The Journal 
of Experimental Medicine by Zanzami, et al. (31) brings mito- 
chondria back in the apoptosis limelight under a new con- 
text, as potentially important in generating nuclear damage 
via a pathway independent  of ROS. Briefly, these authors 
postulate that a crucial,  common step in programmed cell 
death is the opening of mitochondrial "megachannels" by 
the so-called permeability transition (PT), with release of a 
soluble factor that suffices to trigger nuclear apoptosis. Sev- 
eral lines of evidence support their view: (a) a reduction in 
mitochondrial potential, which is a consequence of the PT, 
is an early event after triggering apoptotic  death in many 
systems (32,  33);  (b) isolated mitochondria undergoing PT 
induce nuclear apoptosis in a cell-free model system (this is 
significantly simpler than previously described cell-free ap- 
optosis  systems);  (c)  atractyloside,  an  agent  that  facilitates 
opening  of megachannels,  induces  apoptosis.  Conversely, 
bongkreik acid, which blocks the PT, impairs the ability of 
mitochondria to trigger nuclear  condensation;  (d)  overex- 
pression of Bcl-2 inhibits the PT and thereby seems to pre- 
vent apoptosis.  The  soluble  factor released by mitochon- 
dria, preliminarily described in the report by Zanzami et al. 
(31),  does not appear to be an ROS, as it is not neutralized 
by antioxidants like trolox. Instead, it appears to be a com- 
paratively large (>10 kD), heat-sensitive molecule, likely a 
protein.  It is not seemingly an ICE-related protease, since 
its  action  is  not  blocked  by inhibitors  of these  enzymes. 
Clearly,  the  identity  of the  putative  mediator remains an 
unanswered issue of great urgency. 
How  can  these  notions  be  reconciled  with  the  earlier 
findings  in  p~  mitochondria,  which  lack  mitochondrial 
DNA? Zanzami et al.  (31)  point out that,  despite the ab- 
sence  of a  functional  respiratory  chain,  p~ mitochondria 
maintain their permeability barrier and in fact display a siz- 
able  inner  membrane potential,  maintained  by glycolytic 
ATP. Moreover, such mitochondria undergo swelling, in- 
dicative of the PT, when treated with atractyloside. There- 
fore, while production ofP,  OS by the respiratory chain can 
be ruled  out,  the  opening of megachannels could  control 
apoptosis in  p~ cells,  as it is proposed to  do  in  cells  with 
normal mitochondria.  Opening  of PT  and  release  of the 
apoptosis mediator represent an attractive model to account 
for programmed cell death,  in that opening of the mega- 
channels  could  be  a  convenient  site  for  convergence  of 
multiple  signals.  The  PT  is  induced  and/or  facilitated by 
changes in  calcium concentration,  redox potential,  meta- 
boric state of the cell,  and mitochondrial inner membrane 
electrical potential.  All of these have been earlier invoked 
in the genesis or signaling of apoptosis. Hence, megachan- 
nels may provide an effective integrator of multiple mea- 
sures of cellular status,  explaining the seemingly pleiotropic 
character of programmed death. 
How  the  mitochondrial  permeability transition  is  trig- 
gered by the various apoptotic stimuli remains unknown, 
but one can speculate that ICE-like proteases are involved. 
If this  is  the  case,  the  proteases  may not  be  quite  as  far 
downstream  death  effectors  as  some  had  imagined.  Pro- 
grammed cell death remains a complex phenomenon,  and 
at present no single scheme can accommodate all the avail- 
able information, particularly that relating to bcl-2. Never- 
theless, in view of the findings of Zanzami and colleagues 
(31,  34,  35),  mitochondria seem to have been resurrected 
as worthy contenders in apoptotic signaling. 
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